| Literature DB >> 25642423 |
Akikazu Sakudo1, Takashi Onodera2.
Abstract
Elucidation of prion protein (PrP) functions is crucial to fully understand prion diseases. A major approach to studying PrP functions is the use of PrP gene-knockout (Prnp (-/-)) mice. So far, six types of Prnp (-/-) mice have been generated, demonstrating the promiscuous functions of PrP. Recently, other PrP family members, such as Doppel and Shadoo, have been found. However, information obtained from comparative studies of structural and functional analyses of these PrP family proteins do not fully reveal PrP functions. Recently, varieties of Prnp (-/-) cell lines established from Prnp (-/-) mice have contributed to the analysis of PrP functions. In this mini-review, we focus on Prnp (-/-) cell lines and summarize currently available Prnp (-/-) cell lines and their characterizations. In addition, we introduce the recent advances in the methodology of cell line generation with knockout or knockdown of the PrP gene. We also discuss how these cell lines have provided valuable insights into PrP functions and show future perspectives.Entities:
Keywords: Doppel; Prnp−/− cell line; Shadoo; knockout mouse; prion protein
Year: 2015 PMID: 25642423 PMCID: PMC4295555 DOI: 10.3389/fcell.2014.00075
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
Figure 1Knockout constructs of type-1 and type-2 of prion protein gene (. Structures of the constructs used to produce six lines of Prnp−/− mice. The Prnp−/− mice are divided into type-1 and type-2 Prnp−/− mice depending on whether the splicing acceptor of exon 3 is disrupted. The disruption of exon 3 is correlated with the development of late-onset ataxia and Purkinje cell loss, which is induced by ectopic expression of Doppel (Dpl) in the central nervous system (CNS). The structure of wild-type (WT) Prnp exon 3 and prion protein (PrP) coding region (green box) is shown at the top. The selection markers are indicated by orange boxes. The presence and absence of the exon 3 splicing acceptor (SA) is correlated with the development of late-onset ataxia. The selection markers were PGK, mouse phosphoglycerate kinase promoter; NEO, neomycin phosphotransferase; HPRT, mouse hypoxanthine phosphoribosyltransferase; TK, human herpes simplex virus type 1 thymidine kinase promoter; MT, mouse metallothionein promoter; loxP, a 34-bp recombination site from phage P1.
Figure 2Types of . Currently available Prnp−/− cell lines can be divided into four types i.e., neuronal cells (HpL3-4, Zpl2-1, NpL2, F14), astroglial cells (GpL1), macrophage/microglia (MpLZ, MG0), and fibroblasts (SFK-B, SFK-C, PrP0/0/1).
Figure 3Schematic representations of PrP deletion mutants or PrP-Dpl fusion proteins and . Schematic representations of deletion mutants of mouse PrP and PrP-Dpl fusion protein are shown. Mutants of mouse PrP [PrP: wild-type PrP; Δ#1, PrP(Δ53-94, Q52H); Δ#2, PrP(Δ95-132); Δ#3, PrP(Δ124-146)] were prepared using restriction digestion/ligation. Schematic locations of the deletions as compared with the wild-type protein are shown by a space within the bar next to the indicated protein. Dpl lacks sequences homologous to the octapeptide repeat (OR) and hydrophobic regions (HR) of PrP. ORDpl [PrP(1-95)-Dpl] is Dpl fused with amino acid residues 1-95 of PrP containing the OR. ORHRDpl [PrP(1-124)-Dpl] is Dpl fused with amino acid residues 1-124 of PrP containing the OR and N-terminal half of HR. The numbers refer to the amino acid residues in the mouse PrP sequence or Dpl sequence. The Asn-linked glycosylation sites (CHO), signal peptide sequence (SP), octapeptide repeat region (OR) and hydrophobic region (HR) are shown. The regions forming an α-helix secondary structure are shown as α1-α3, whereas those forming a β-sheet are shown as β 1 and β 2. Both PrP and Dpl have a glycosylphosphatidylinositol (GPI) anchor attached to its C-terminus. HpL3-4 cells expressing wild-type PrP (PrP), PrP(Δ53-94, Q52H) (Δ#1), PrP(Δ95-132) (Δ#2), PrP(Δ124-146) (Δ#3), Dpl (Dpl), PrP(1-95)-Dpl (ORDpl), PrP(1-124)-Dpl (ORHRDpl) or the empty vector alone (EM) were serum-deprived. The rate of apoptosis of the cells after serum deprivation for 24 h is shown on the right. The number of pluses (+) indicates the degree of apoptosis. Minus (−) indicates a lesser degree of apoptosis. Updated from Figure 4 in Sakudo et al. (2006) and Figure 3 in Sakudo et al. (2007b) with permission from Bentham Science Publishers, Ltd. and John Wiley & Sons, Inc., respectively.
.
| HpL2-1, HpL3-2, HpL4-3 | Retrovirus-mediated method by SV40 large T antigen expressing vector | Neuronal-precursor cells (expessing NF- 68K) | Rikn | 10% FCS-DMEM | Susceptible to serum deprivation | Kuwahara et al., |
| Zpl2-1, Zpl2-4, Zpl3-4 | Lipofection of SV40 large T antigen expressing vector | Neuronal cells (expressing NeuN) | ZrchI | DMEM | Higher prolifertion rate | Kim et al., |
| SFK-B, SFK-C | Continuous culture of abdominal skin explants | Skin fibroblast cells | Ngsk | 10% FCS-DMEM | Decreased expression of Ras and Rac related proteins | Satoh et al., |
| F14 | Fusion of PrP-knockout cerebellar cells and mouse neuroblastoma cells | Neuronal cells (expressing NeuN, MAP-2, and synaptophysin) | Npu | Serum containing DMEM | Similar distribution of GFP-PrP fusion protein | Holme et al., |
| NpL2 | Retrovirus-mediated method by SV40 large T antigen expressing vector | Neuronal cells (expressing NF-L, NF-M, NF-H, and MAP-2) | ZrchI | 10% FCS-NB/B27 medium | Susceptible to serum deprivation | Nishimura et al., |
| MG0 | Retrovirus-mediated method by c-myc expressing vector | Microglial cell (expressing Mac-1 and F4/80) | Rikn | 10% FCS-DMEM supplemented with 100 μM β-mercaptoethanol, 10 μg/ml insulin | Comparison has not been performed | Iwamaru et al., |
| MpLZ4-3 | Retrovirus-mediated method by SV40 large T antigen expressing vector | Macrophage (expressing MOMA-2 and F4/80) | ZrchI | 10% FCS-DMEM | Shorter pseudopodium extension and less phagocytotic activity | Uraki et al., |
| PrP0/0/1 | Treatment with chemical mutagen (3-methylcholanthrene) | Embryonic fibroblast (expressing fibronectin) | Ngsk | 10% FCS-MEMD supplemented with 2 mM-glutamine | Higher prolifertion rate (probably artificial) | Prcina et al., |
| GpL1 | Retrovirus-mediated method by SV40 large T antigen expressing vector | Glial cells (expressing GFAP) | ZrchI | 10% FCS-DMEM | Susceptible to serum deprivation | Nishimura et al., |
DMEM, Dulbecco's modified Eagle's medium.
MCA, Methylcholanthrene, which is a highly carcinogenic polycyclic aromatic hydrocarbon produced by burning organic compounds at very high temperatures.
NB/B27 medium, neurobasal medium (NB) (Gibco BRL, Gaithersburg, MD, USA) supplemented with B27 supplement (B27) (Gibco) and glutamine.
Updated from Table 3 in Sakudo et al. (.
Abnormality of PrP gene-deficient cell lines.
| HpL2-1, HpL3-2, HpL4-3 | Higher rate of apoptosis by serum deprivation | Kuwahara et al., |
| HpL3-4 | Decrease of intracellular copper concentration after serum deprivation | Sakudo et al., |
| HpL3-4 | Decrease of cellular SOD activity | Sakudo et al., |
| HpL3-4 | Bigger increase of intracellular superoxide anion after serum deprivation | Sakudo et al., |
| HpL3-4 | Reduced increase of intracellular hydrogen peroxide after serum deprivation | Sakudo et al., |
| HpL3-4 | Bigger increase of caspase-3/9 activation after serum deprivation | Sakudo et al., |
| HpL3-4 | Increased sensitivity of poliovirus infection | Baj et al., |
| HpL3-4 | Increased coxsackievirus B3 production and apoptotic cell death | Nakamura et al., |
| HpL3-4 | Alteration of Ca2+ concentration in mitochondria after serum deprivation | Kim et al., |
| HpL3-4 | Alteration of transmembrane potentials in mitochondria after serum deprivation | Kim et al., |
| HpL3-4 | Alteration of cytochrome c level in mitochondria after serum deprivation | Kim et al., |
| HpL3-4 | Higher rate of apoptosis by SIN-1 | Vassallo et al., |
| HpL3-4 | Reduced PI 3-kinase activity | Vassallo et al., |
| HpL3-4 | Decrease of cellular viability | Mange et al., |
| HpL3-4 | Shorter neurite extension after differentiation | Kuwahara et al., |
| HpL3-4 | Suceptible to amyloid beta toxicity and amyloid beta-inducing autophagy | Nah et al., |
| HpL3-4 | Decreased rise in intracellular calcium following hydrogen peroxide treatment | Krebs et al., |
| HpL3-4 | Neutralization of Dpl toxicity | Sakudo et al., |
| NpL2 | Decrease of SOD activity | Nishimura et al., |
| NpL2 | Higher rate of apoptosis by serum deprivation | Nishimura et al., |
| Zpl2-1, Zpl2-4, Zpl3-4 | Higher prolifertion rate | Kim et al., |
| Zpl3-4 | Increased autophagy induced by serum deprivation | Oh et al., |
| Zpl3-4 | Higher rate of apoptosis and autophagy by serum deprivation | Oh et al., |
| GpL1 | Decrease of SOD activity | Nishimura et al., |
| GpL1 | Higher rate of apoptosis by serum deprivation | Nishimura et al., |
| GpL1 | Decrease of cellular viability of co-cultured neuronal cells | Onodera and Sakudo, unpublished results |
| MplZ3-4 | Shorter pseudopedium extension and reduced phagocytotic activity | Uraki et al., |
| PrP0/0/1 | Higher proliferation rate (may be non-specific) | Prcina et al., |
| SFK-B, SFK-C | Decreased expression of Ras and Rac related proteins | Satoh et al., |
PI3, phosphatidylinositol 3.
SIN-1, 3-morpholinosydnonimine.
SOD, superoxide dismutase.
Updated from Table 4 in Sakudo et al. (.
Figure 4Strategies for obtaining cell lines in which . Established Prnp−/− cell lines can be obtained from a number of distributors. If suppression of Prnp is required, rather than a knockout of Prnp, gene silencing technology using siRNA (small interference RNA), miRNA (micro-RNA) bi-shRNA (bifunctional short hairpin RNA) or shRNA (short hairpin RNA) is applicable. In other cases, when a new Prnp−/− cell line is generated, immortalization of cells derived from Prnp−/− mice is usually performed. Alternatively, gene editing techniques such as CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat), ZFN (Zinc Finger Nuclease), or TALEN (Transcription activator-like effector nuclease) can be used to knockout Prnp, resulting in the production of Prnp+/− or Prnp−/− cell lines. Cells can be immortalized using oncogene transfection, radiation, fusion with cancer cells, or treatment with chemical mutagens. In other cases, cells derived from transgenic mice with an oncogene (e.g., temperature sensitive SV40 (Simian virus 40) large T, p53 etc.) that is overexpressed, mutated or deleted can proliferate and be maintained in culture medium. Continuous fibroblast culture can also be used. A cell line may be established after cloning and selection of these cells.